CREDIT AGREEMENT Dated as of November 29, 2016 among BIOMARIN PHARMACEUTICAL INC., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender, L/C Issuer and a Lender, and the other Lenders from time to time party heretoCredit Agreement • February 27th, 2017 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
This CREDIT AGREEMENT (“Agreement”) is entered into as of November 29, 2016, among BIOMARIN PHARMACEUTICAL INC., a Delaware corporation (the “Borrower”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer.
BIOMARIN PHARMACEUTICAL INC. Amended and Restated 2006 Share Incentive Plan Agreement Regarding Performance Compensation Award in the Form of Restricted Stock UnitsShare Incentive Plan Agreement • February 27th, 2017 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
Unless otherwise defined herein, all capitalized terms used in this Agreement Regarding Performance Compensation Award in the Form of Restricted Stock Units (this “Award Agreement”) shall have the meanings attributed thereto in the Amended and Restated BioMarin Pharmaceutical Inc. 2006 Share Incentive Plan (as amended, the “Plan”). By executing this Award Agreement, you agree to be bound by all of the provisions of the Plan applicable to an award of restricted stock units and performance units made pursuant to the Plan (including without limitation, the terms and conditions set forth in Sections 10, 11, 12, 14, 17, 20, 21, 22, 23 and 24 of the Plan), the provisions of which are hereby made a part of this Award and incorporated herein by reference, and all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of this Award and those of the Plan, the provisions o
FIRST AMENDMENT TO THETermination and Transition Agreement • February 27th, 2017 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
This First Amendment to the AMENDED AND RESTATED TERMINATION AND TRANSITION AGREEMENT (“First Amendment”) is made on December 12, 2016 (“First Amendment Effective Date”) by and between:
